컨텐츠로 이동
The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics 해당 항목을 미리보기
닫기해당 항목을 미리보기
확인중입니다…

The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics

저자: J Geigert
출판사: New York, NY : Springer, ©2013.
판/형식:   전자도서 : 문서 : 영어 : 2nd ed모든 판과 형식 보기
데이터베이스:WorldCat
요약:
An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in  더 읽기…
평가:

(아무런 평가가 없습니다.) 0 리뷰와 함께 - 첫번째로 올려주세요.

주제
다음과 같습니다:

 

온라인으로 문서 찾기

이 항목에 대한 링크

도서관에서 사본 찾기

&AllPage.SpinnerRetrieving; 해당항목을 보유하고 있는 도서관을 찾는 중

상세정보

장르/형태: Electronic books
자료 유형: 문서, 인터넷 자료
문서 형식: 인터넷 자원, 컴퓨터 파일
모든 저자 / 참여자: J Geigert
ISBN: 9781461469162 1461469163
OCLC 번호: 843402928
설명: 1 online resource.
내용: Complexity of biologic CMC regulation --
Biologics are not chemical drugs --
An effective CMC strategy is possible --
Challenge of adventitious agent control --
Source materials for biologics --
Manufacture of the biologic API --
The biologic final product process --
Complex process-related impurities --
Molecular structural analysis --
Functional activity (Potency) --
Setting specifications and expiry dates --
Demonstrating product comparability --
CMC-focused regulatory meetings.
책임: John Geigert.
더 많은 정보:

초록:

In its new edition, this book reviews the challenges facing quality assurance and control (QA/QC) in today's biopharmaceutical environment, putting into perspective the need for a graded approach to  더 읽기…

리뷰

사용자-기여 리뷰
GoodReads 리뷰 가져오는 중…
DOGObooks 리뷰를 가지고 오는 중…

태그

첫번째 되기
요청하신 것을 확인하기

이 항목을 이미 요청하셨을 수도 있습니다. 만약 이 요청을 계속해서 진행하시려면 Ok을 선택하세요.

링크된 데이터


<http://www.worldcat.org/oclc/843402928>
library:oclcnum"843402928"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/843402928>
rdf:typeschema:Book
schema:about
schema:about
schema:about
<http://id.loc.gov/authorities/subjects/sh00005579>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology industry--Law and legislation."
schema:about
<http://id.worldcat.org/fast/1060114>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology industry--Law and legislation"
schema:about
<http://id.worldcat.org/fast/1060109>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology--Quality control"
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
<http://id.loc.gov/authorities/subjects/sh90004049>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology--Quality control."
schema:name"Pharmaceutical biotechnology."
schema:about
schema:bookEdition"2nd ed."
schema:bookFormatschema:EBook
schema:copyrightYear"2013"
schema:creator
schema:datePublished"2013"
schema:description"An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years. So much has changed since the 1st edition of this book was published in 2004. There are now additional manufacturing processes for producing commercial biopharmaceuticals - transgenic plant cell cultures and transgenic animals. In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy). Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA. Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu). Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS). The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition. All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals). About The Author John Geigert is President of BioPharmaceutical Quality Solutions, which specializes in providing CMC regulatory strategy consulting for the biopharmaceutical and biologic industry. Dr. Geigert has over 35 years of CMC industrial experience and leadership in the biopharmaceutical industry. Dr. Geigert has served on the PDA Board of Directors, co-chaired the PDA Biotech Advisory Board and served as an expert member of the USP Biotechnology Committee. Dr. Geigert has written extensively for the Regulatory Affairs Professional Society (RAPS) Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series) and Demystifying CMC Regulatory Strategy (Sept 2011-Mar 2012, 4-part series))."
schema:exampleOfWork<http://worldcat.org/entity/work/id/673009>
schema:genre"Electronic books."
schema:inLanguage"en"
schema:name"The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics"
schema:publisher
schema:url<http://dx.doi.org/10.1007/978-1-4614-6916-2>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=580248>
schema:url
schema:url<http://site.ebrary.com/id/10699675>
schema:workExample

Content-negotiable representations

윈도우 닫기

WorldCat에 로그인 하십시오 

계정이 없으세요? 아주 간단한 절차를 통하여 무료 계정을 만드실 수 있습니다.